1. In Vivo
  2. >>Innovation

Why Protein Misfolding Diseases Have Been Pharma’s Achilles Heel

 
• By Eliza Slawther

Protein misfolding diseases, such as Alzheimer’s, are still largely untreatable and incurable. A leading scientist explains why these diseases pose unique R&D challenges and how researchers are beginning to overcome them.  

AchillesHeel
• Source: Shutterstock

Protein misfolding diseases, such as Alzheimer’s, have attracted much investment and interest from pharma – yet little progress has been made in developing drug candidates for these diseases.

Alzheimer’s has been in the pharma spotlight perhaps the most of all the amyloid associated diseases in recent years, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.